Arecor

Arecor is a UK-based biopharma company utilizing its Arestat® formulation technology to create superior drug products in diabetes and cardiometabolic diseases. The company has a dual strategy: advancing its own clinical-stage pipeline of next-generation insulins and developing an oral peptide delivery platform, while also generating revenue through technology licensing partnerships. With one partnered product already on the market generating royalties and a robust intellectual property portfolio, Arecor aims to improve patient outcomes through enhanced drug delivery.

Arestat® technology platform: a formulation science platform used to enhance the stability, concentration, delivery route (e.g., IV to SC, oral peptides), and performance of biologics, peptides, antibodies, and vaccines.

Arecor competes in the diabetes drug delivery space against large insulin manufacturers (Novo Nordisk, Sanofi, Eli Lilly) and biotech firms developing novel formulations. Its Arestat® platform also competes with other drug formulation and delivery technology companies. Differentiation is based on demonstrated stability and performance enhancements and a strong IP portfolio.